BioCryst Pharmaceuticals, Inc., a biotechnology company, engages in the design, optimization, and development of drugs that block key enzymes involved in cancer, viral infections, and autoimmune diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. The company?s product candidates include forodesine HCl, a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP), which is in Phase IIb clinical trial for patients with Cutaneous T-cell Lymphoma (CTCL); and in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its Forodesine HCl product is used for three indications: T-cell non-Hodgkin lymphoma, including CTCL; CLL and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-cell acute lymphoblastic leukemia. The company also provides peramivir, an inhibitor of influenza neuraminidase, which completed Phase II clinical trial for the treatment of influenza with two parenteral formulations, intramuscular and intravenous. In addition, it offers BCX-4208/R3421, a second generation PNP inhibitor, which is in the Phase IIa clinical trial for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases. The company has collaborative and other research and development contracts with Shionogi & Co., Ltd.; U.S. Department of Health and Human Services; Green Cross Corporation; Mundipharma International Holdings Limited; F.Hoffmann-La Roche Ltd. and Hoffman-La Roche Inc.; Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.; The University of Alabama at Birmingham; and Emory University. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama.